Zepbound vs Wegovy Pill
Side-by-side on efficacy, form, dosing, side effects, and 2026 cash-pay and insurance pricing.
| Zepbound | Wegovy Pill | |
|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide |
| Form | Injection | Daily pill |
| Avg weight loss | ~22.5% | ~15% |
| Cash price / mo | $299–$499 | $149–$299 |
| FDA for obesity | Approved | Approved |
If weight-loss efficacy is the priority and you'll accept injections, Zepbound wins clearly (22.5% vs 13.6%). If avoiding injections is non-negotiable, the Wegovy Pill is the best approved option in 2026. Oral GLP-1s with Zepbound-level efficacy (notably orforglipron, expected 2026–2027) are coming but not yet approved.
Who wins on what
The injection/oral trade-off
In 2026, the approved oral GLP-1 options are still efficacy-limited compared to the best injections. The Wegovy Pill at 13.6% weight loss is the first oral drug to reach mainstream clinical utility for obesity, but it's still roughly 9 percentage points below Zepbound at 15 mg. Orforglipron, an oral small-molecule GLP-1 expected to file in 2026, is projected to close that gap.
Until then, the honest trade-off is: needles for more weight loss, or no needles for less weight loss.
Efficacy
Zepbound 15 mg: 22.5% (SURMOUNT-1). Wegovy Pill 25 mg: 13.6% (OASIS-4). The gap is larger than either drug versus placebo.
For a patient who can tolerate weekly injections, Zepbound is almost always the efficacy-rational pick. For a patient with true needle aversion or a lifestyle that makes injection supply logistics hard (very frequent travel without refrigeration), the Wegovy Pill is the best approved oral option.
Cost, side effects, and access
Both are roughly in the same cash-pay range ($349 vs $499). Both have similar class-level side effects. Wegovy Pill's strict fasting protocol is an adherence risk that Zepbound's weekly injection doesn't have.
If cost is tied and efficacy matters, Zepbound. If no-needles is non-negotiable, Wegovy Pill. If you can wait 12–18 months, oral orforglipron is likely to reshape this decision.
Frequently asked questions
Is there a pill version of Zepbound?
Not yet. Lilly has oral tirzepatide analogs in early development, but there is no pill version of Zepbound approved in the U.S. as of April 2026. Lilly's oral GLP-1 drug in late development is orforglipron (a different molecule, small-molecule GLP-1 only), expected 2026–2027.
Is the Wegovy Pill ever going to match Zepbound?
Unlikely at current doses. Higher-dose oral semaglutide (50 mg) showed larger effects in diabetes trials and is expected to seek obesity approval, but still probably won't match tirzepatide's dual-mechanism efficacy. Orforglipron and future triple-agonist orals are the more likely path to oral-Zepbound-equivalence.
Can I switch between Zepbound and the Wegovy Pill?
Yes — different molecules but similar class. Most prescribers transition at a pharmacokinetically conservative dose (Zepbound 5–7.5 mg → Wegovy Pill 14 mg for 4 weeks → 25 mg) to minimize GI relapse.
Not sure which is right for you? Take the Sherpa Matcher — it accounts for your goals, budget, and insurance in 60 seconds.